Status:

UNKNOWN

Chemoprevention Efficacy Study Nigeria

Lead Sponsor:

Malaria Consortium

Conditions:

Malaria

Eligibility:

All Genders

3-59 years

Phase:

PHASE4

Brief Summary

The study aims to assess the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and Amodiaquine (SPAQ) used in standard age-based dosing regimens used in Seasonal Malaria Chemoprevention (SMC) and ...

Detailed Description

The study aims (1) to determine the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and Amodiaquine (SPAQ) used in standard age-based dosing regimens for Seasonal Malaria Chemoprevention (SMC) i...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Children between 3-59 months.
  • Being resident in the research study area.
  • Afebrile children with no other malaria associated symptoms in the past 48 hours or at time of recruitment.
  • Consent to participate in the study obtained.
  • Can comply with 3 days DOT of standard SPAQ regimen.
  • Willingness and ability of the child's guardians to comply with the study protocol for the duration of the study including all dry blood spot and slide collections.
  • Exclusion criteria
  • Symptoms of malaria (tympanic fever ≥ 37.5 °C or history of fever in past 48 hours)
  • Known allergy to SPAQ.
  • Receiving a sulfa-based medication for treatment or prophylaxis, including co-trimoxazole (trimethoprim-sulfamethoxazole).
  • Individuals receiving azithromycin due to the antimalarial activity of azithromycin.
  • Severe malnutrition according to WHO guidelines
  • HIV positive or ARV use (SPAQ MUST NEVER be used with children taking the antiretroviral efavirenz)
  • Chronic illness of any kind.
  • Treatment with an ACT in previous 2 weeks.
  • Previous treatment with SPAQ this malaria season.

Exclusion

    Key Trial Info

    Start Date :

    July 28 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    May 15 2024

    Estimated Enrollment :

    800 Patients enrolled

    Trial Details

    Trial ID

    NCT05979896

    Start Date

    July 28 2023

    End Date

    May 15 2024

    Last Update

    August 7 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Kwara Sentinell Site

    Kwara, Nigeria